Browse by UCL people
Group by: Type | Date
Number of items: 14.
Article
Abeyakoon, O;
Latifoltojar, A;
Gong, F;
Papoutsaki, M-V;
Chowdhury, R;
Glaser, M;
Jeraj, H;
... Punwani, S; + view all
(2019)
Hyperpolarised 13C MRI: a new horizon for non-invasive diagnosis of aggressive breast cancer.
BJR case reports
, 5
(3)
, Article 20190026. 10.1259/bjrcr.20190026.
|
 |
|
Bartlett, JMS;
Bayani, J;
Kornaga, E;
Xu, K;
Pond, GR;
Piper, T;
Mallon, E;
... Rea, D; + view all
(2021)
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.
NPJ Breast Cancer
, 7
(1)
, Article 90. 10.1038/s41523-021-00297-7.
|
|
|
Bartlett, JMS;
Bayani, J;
Kornaga, EN;
Danaher, P;
Crozier, C;
Piper, T;
Yao, CQ;
... Stein, RC; + view all
(2020)
Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training.
PLOS ONE
, 15
(9)
, Article e0238593. 10.1371/journal.pone.0238593.
|
|
|
Eccles, SA;
Aboagye, EO;
Ali, S;
Anderson, AS;
Armes, J;
Berditchevski, F;
Blaydes, JP;
... Thompson, AM; + view all
(2013)
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Breast Cancer Research
, 15
(5)
, Article R92. 10.1186/bcr3493.
|
|
Jepson, M;
Elliott, D;
Conefrey, C;
Wade, J;
Rooshenas, L;
Wilson, C;
Beard, D;
... OPTIMA prelim study group, .; + view all
(2018)
An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment.
Journal of Clinical Epidemiology
, 99
pp. 75-83.
10.1016/j.jclinepi.2018.02.018.
|
|
|
Kotwinski, PJ;
Smith, G;
Cooper, J;
Sanders, J;
Ma, L;
Teis, A;
Kotwinski, D;
... Breast cancer Early disease: Toxicity from Therapy with Epirubic; + view all
(2016)
Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
PLOS One
, 11
(12)
, Article e0165262. 10.1371/journal.pone.0165262.
|
|
|
Nagano, K;
Akpan, A;
Warnasuriya, G;
Corless, S;
Totty, N;
Yang, A;
Stein, R;
... Naaby-Hansen, S; + view all
(2012)
Functional Proteomic Analysis of Long-term Growth Factor Stimulation and Receptor Tyrosine Kinase Coactivation in Swiss 3T3 Fibroblasts.
Molecular & Cellular Proteomics
, 11
(12)
pp. 1690-1708.
10.1074/mcp.M112.019778.
|
|
|
Pinder, SE;
Campbell, AF;
Bartlett, JMS;
Marshall, A;
Allen, D;
Falzon, M;
Dunn, JA;
... Stein, RC; + view all
(2017)
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
British Journal of Cancer
, 116
(7)
pp. 859-863.
10.1038/bjc.2017.28.
|
|
Rooshenas, L;
Elliott, D;
Wade, J;
Jepson, M;
Paramasivan, S;
Strong, S;
Wilson, C;
... POUT study group; + view all
(2016)
Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials.
PLoS Med
, 13
(10)
, Article e1002147. 10.1371/journal.pmed.1002147.
|
|
|
Rooshenas, L;
Scott, LJ;
Blazeby, JM;
Rogers, CA;
Tilling, KM;
Husbands, S;
Conefrey, C;
... Wheatley, T; + view all
(2019)
The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation.
Journal of Clinical Epidemiology
, 106
pp. 108-120.
10.1016/j.jclinepi.2018.10.004.
|
|
Schmid, P;
Abraham, J;
Chan, S;
Wheatley, D;
Brunt, AM;
Nemsadze, G;
Baird, RD;
... Turner, NC; + view all
(2020)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Journal of Clinical Oncology
, 38
(5)
pp. 423-433.
10.1200/JCO.19.00368.
|
|
Velikova, Galina;
Morden, James P;
Haviland, Joanne S;
Emery, Charlotte;
Barrett-Lee, Peter;
Earl, Helena;
Bloomfield, David;
... Cameron, David; + view all
(2023)
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
The Lancet Oncology
10.1016/s1470-2045(23)00460-6.
(In press).
|
Report
|
Stein, RC;
Dunn, JA;
Bartlett, JMS;
Campbell, AF;
Marshall, A;
Hall, P;
Rooshenas, L;
+ view all
(2016)
OPTIMA: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
(Health Technology Assessment
20(10)
, pp. pp. 1-202
).
National Institute of Health Research: UK.
|
|
Conference item
|
Bell, L;
Potts, H;
Williamson, E;
(2019)
P-17
Improving engagement in a health app: considerations in
designing a Micro-Randomised Trial.
Presented at: The 5th International Clinical Trials Methodology Conference (ICTMC 2019).
|
|
